Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 2
2006 1
2007 1
2008 2
2009 2
2010 1
2012 3
2013 2
2014 2
2016 1
2019 1
2020 1
2021 6
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.
Egawa-Takata T, Ueda Y, Ito K, Hori K, Tadahiro S, Nagasawa T, Nishio S, Ushijima K, Koji N, Enomoto T, Kikuchi A, Honma S, Oishi T, Shimada M, Takei Y, Fujiwara H, Tanabe H, Okamoto A, Nishio Y, Yamada T, Kimura T. Egawa-Takata T, et al. Among authors: koji n. Cancer Sci. 2022 May;113(5):1693-1701. doi: 10.1111/cas.15310. Epub 2022 Mar 10. Cancer Sci. 2022. PMID: 35218673 Free PMC article. Clinical Trial.
Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study.
Yoshihara K, Baba T, Tokunaga H, Nishino K, Sekine M, Takamatsu S, Matsumura N, Yoshida H, Kajiyama H, Shimada M, Kagimura T, Oda K, Sasajima Y, Yaegashi N, Okamoto A, Sugiyama T, Enomoto T. Yoshihara K, et al. Among authors: nishino k. Cancer Sci. 2023 Jun;114(6):2515-2523. doi: 10.1111/cas.15747. Epub 2023 Apr 10. Cancer Sci. 2023. PMID: 36747324 Free PMC article.
Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
Sekine M, Enomoto T, Arai M, Yokoyama S, Nomura H, Nishino K, Ikeuchi T, Kuriyama Y, Nakamura S; Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer. Sekine M, et al. Among authors: nishino k. J Hum Genet. 2022 May;67(5):267-272. doi: 10.1038/s10038-021-01002-z. Epub 2022 Jan 4. J Hum Genet. 2022. PMID: 34983974
32 results